As Monday comes to a close, we've identified some stocks that have had some unusual volume recently which are worth noting. Now let's hop into the details and show you what we found!
DISCOUNT PRINT USA INC. (OTC: DPUI) is a commercial print brokerage firm that provides affordable and top-notch printing services to both individuals and businesses.
On March 7, 2023, DPUI Announced its Entry Into a $50+ Billion US Convention Industry Market. The Company's New Division 'Convention Printing of America' Opened 11 New Local Offices in Key US Cities within the Last 5 Months. Their aggressive plan is to open 39 more Regional US Offices In next 24 months.
On May 4, 2023, the company also announced that it has become an authorized distributor for 'Showdown Displays'. The deal adds over 1,000 new products that the company can offer to exhibitors attending trade shows in America. The Global Event and Exhibition Market is anticipated to reach $50 Billion by 2027.
Currently, the stock has some support in the high trip $0.000 range and there are indications of a potential breakout. It experienced a notable increase, closing the yesterday with a 29% gain, accompanied by a high trading volume of 41 million shares, surpassing the average daily volume. Due to these factors, it is recommended to monitor this stock closely as it may have further upside potential in the near future.
Reelcause, Inc. (OTC: RCIT) is dedicated to safeguarding the global environment alongside the global community through the revitalization of hydrogen energy as part of their comprehensive renewable energy policy. By embracing this sustainable energy source, they aim to significantly reduce global greenhouse gas emissions. Their future objective is to participate in the global carbon emission exchange business and emerge as a prominent leader in the global carbon reduction movement. They've established partnerships with a state-run research institute that possesses cutting-edge patent technology in hydrogen energy from the former Soviet Union, as well as Hienergy Global USA. Leveraging the support of small wind power generators, they're actively developing a range of innovative products that combine wind energy with hydrogen energy, further advancing renewable energy solutions. In the coming years, Reelcause will work towards entering the global carbon credit exchange market and strive to become a prominent player in the worldwide carbon reduction initiative. Their product family includes a diverse range of hydrogen-based solutions such as hydrogen gas ranges, hydrogen boilers, hydrogen-powered hot air fans, hydrogen water purifiers, hydrogen wave energy systems, hydrogen drones, hydrogen energy farms, and the realization of intelligent farming through the use of hydrogen boilers.
Although the company has not issued any press releases in the past few years, there have been intermittent surges in trading volume for this stock recently, which is quite unusual. It is worth noting that the stock has a relatively low float of 13 million shares and a market capitalization of $1.6 million, indicating the potential for significant opportunities and substantial price movements.
ViaDerma, Inc. (OTC: VDRM) is a pharmaceutical company dedicated to advancing the pharmaceutical industry by conducting innovative research and development to introduce novel products. The company specializes in manufacturing and marketing a wide range of medical products, addressing various fields such as infectious diseases and stem-cell therapy. These products are typically administered topically, utilizing an exclusive delivery system technology that is currently pending a patent. While currently focused on over-the-counter (OTC) drugs, which do not require a prescription, ViaDerma believes that this delivery system can also be applied to prescription medications. This extends not only to topical prescriptions but also has the potential to transform certain oral medications into topical formulations. Apart from the primary objective of developing and commercializing new products, ViaDerma is actively exploring opportunities to license its technology to other pharmaceutical companies.
ViaDerma, Inc. provided an update on its ongoing business activities on March 02, 2023.
?An expanded licensing agreement has been secured by ViaDerma with a prominent wound care network. The licensee has recently expanded its operations to cover eleven states, leading to increased royalties for ViaDerma. As per the agreement, ViaDerma receives a monthly payment of $5,000 for each state where the licensee operates. With the addition of these new states, ViaDerma's current royalties from this agreement now amount to $55,000 per month. The wound care network has expressed its intention to accelerate the expansion and aims to achieve nationwide coverage within the next twelve months.
?ViaDerma has successfully launched its new corporate website, now accessible at ViaDerma.com. This website redesign is a significant step in the company's ongoing efforts to enhance brand recognition, engage with customers, and attract new business opportunities on a global scale.
?ViaDerma is actively pursuing approval for insurance coverage benefits for its products, Vitastem and Vitastem Ultra. Many insurance companies, including Medicare and Medicaid, offer coverage for over-the-counter (OTC) products, such as the ones offered by ViaDerma. Seeking insurance coverage approval aligns with ViaDerma's strategy to increase accessibility and affordability of its products for customers.
Also, on July 06, 2023, ViaDerma, Inc. shared a series of exciting updates regarding its business operations, aimed at current and potential shareholders, partners, and healthcare providers.
Regarding the distribution of their flagship product, Vitastem Ultra, ViaDerma has made significant progress in meeting the stability testing requirements. These tests are essential for obtaining approvals to distribute the product in multiple countries across the Caribbean and Middle East. The company has completed over 30% of the required testing protocols, and based on the feedback received thus far, they anticipate finalizing the testing by the end of August or early September of this year.
In relation to their hair regrowth product, Nupelo, ViaDerma is in the final stages of securing FDA-registered product approval. The company's team has received feedback from the FDA, which included a request for additional information necessary for the final approval process. ViaDerma promptly submitted the required information to the FDA in early June and is now eagerly awaiting confirmation of FDA-registered approval for Nupelo, which is expected to be received imminently.
Furthermore, ViaDerma has been actively engaging with auditors, CPA firms, and attorneys, and is in the process of selecting the appropriate service providers to complete two years of audited financial statements. This step is essential for ViaDerma to achieve full SEC reporting compliance. Once the audit is successfully completed, the company intends to promptly apply for uplisting ViaDerma to the OTCQB, a trading platform for early-stage and developing companies.
There has been a notable increase in trading volume for the stock recently, and it closed yesterday with a 7% gain. The trading volume reached 7.8 million shares for the day. Given these developments, it would be prudent to monitor this stock closely as it may have further potential for upside in the near future.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.
CONTACT: CONTACT: https://bigtimepennystocks.com/
Editor: mail@bigtimepennystocks.com
.
DISCOUNT PRINT USA, INC. 
